Mubritinib
Tools
Actions
General
Print/export
Print/export
In other projects
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by 104.153.72.218 (talk) at 06:10, 7 October 2017 (Use corret png structure instead of incorrect svg.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:10, 7 October 2017 by 104.153.72.218 (talk) (Use corret png structure instead of incorrect svg.)
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H23F3N4O2 |
Molar mass | 468.47 g/mol g·mol−1 |
3D model (JSmol) | |
|
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]
Synthesis
See also
References
- ^ McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X.
- ^ Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
- ^ Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6.
- ^ "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View - ClinicalTrials.gov".
CI monoclonal antibodies ("-mab") |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Tyrosine kinase inhibitors ("-nib") |
| ||||||||
Other |
|
Angiopoietin |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) |
| ||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|